Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The Phase 2 trial of efimosfermin alfa (BOS-580) shows that once-monthly dosing is safe and well-tolerated in patients with MASH and F2/F3 fibrosis, supporting its continued clinical development as a potential liver-targeted therapy.
A nationwide study reveals that adolescent liver transplant recipients receiving grafts from donors 10+ years older face a 12.7% reduction in 10-year graft survival. Expanding allocation radii could improve access to age-matched organs and
A massive cohort study reveals that colorectal adenoma recurrence risk is not static; high-grade dysplasia, villous histology, obesity, and sex-based factors exhibit distinct time-varying patterns, necessitating a shift toward personalized,
A prospective study of 18,838 adults reveals that glycemically defined new-onset diabetes (GNOD) significantly increases the 3-year risk of pancreatic cancer, with notable racial variations and a critical 8-month diagnostic window.
A Phase 2 trial of NG101 for gastroparesis missed its primary endpoint for nausea severity on the DIGS-DD scale but demonstrated significant improvements in Patient Global Impression of Change (PGIC) and a favorable safety profile, particul
This Phase 2 trial of NG101 for gastroparesis did not meet its primary endpoint for nausea severity reduction but showed significant global improvement in patient-reported outcomes and a favorable safety profile, particularly in idiopathic
This article examines the Phase 2 trial of NG101 (metopimazine), a novel treatment for gastroparesis. While the primary endpoint was missed, significant improvements in patient-reported outcomes and a strong safety profile suggest a potenti
The PAMORA-RAP trial suggests that naldemedine, a peripherally acting μ-opioid receptor antagonist, may reduce the risk of recurrent acute pancreatitis by nearly 50%, offering a potential first-in-class pharmacological strategy for this hig
The SHARP randomized clinical trial finds that minor papillotomy does not significantly reduce the risk of recurrent acute pancreatitis in patients with pancreas divisum. These results challenge long-standing clinical practices and emphasiz
This large-scale prospective cohort study identifies specific spleen length and volume thresholds that significantly increase the 5-year risk of hematologic malignancies and liver disease, providing a data-driven framework for clinical work
The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-mont
A randomized clinical trial published in the Annals of Internal Medicine reveals that the Mediterranean diet is superior to traditional dietary advice for managing IBS symptoms, offering a nutrient-dense, sustainable first-line intervention
A randomized controlled trial demonstrates that early interactive human coaching via a mobile app improves long-term quality of life, reduces dyspnea, and eases eating restrictions in postgastrectomy patients, particularly among younger and
A multicenter RCT demonstrates that preoperative nutritional support reduces the incidence of Hirschsprung-associated enterocolitis (HAEC) from 29.09% to 7.27%, offering a critical strategy for improving surgical outcomes in pediatric patie
A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving
Clinical trials reveal that Rifaximin provides faster symptom relief and significantly better adherence than the low FODMAP diet in IBS patients, while also potentially restoring lactase activity in those with small intestinal bacterial ove
A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr
A multicenter RCT found that ethosuximide, a T-type calcium channel blocker, did not improve abdominal pain in IBS patients compared to placebo and was associated with significant tolerability issues, highlighting the need for more selectiv
This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
Open language-specific specialty feeds and department pages.